The medical/pharmaceutical chemistry Innovation Award is awarded by the Division of Medicinal Chemistry of the German Chemical Society (GDCh) together with the pharmaceutical/medicinal chemistry Division of the German Pharmaceutical Society (DPhG). The prize honors outstanding scientific publications and results in the fields of medicinal and pharmaceutical chemistry. The award comes with a certificate of award and prize money of 5,000 euros donated by the two Divisions . The award usually takes place annually as part of the "Frontiers in Medicinal Chemistry" Conference . The prize can be shared.
Deadline: November 30, 2023
Every year, the GDCh Division of Medicinal Chemistry and the DPhG Division for pharmaceutical/medicinal chemistry jointly award this prize in recognition of outstanding and independent scientific research in medicinal and pharmaceutical chemistry – evidenced by publications in scientific journals.
The award comes with a certificate of award and prize money of 5,000 euros donated by the two Divisions . The prize can be shared. The award will be presented at the Frontiers in Medicinal Chemistry Conference , which will take place from March 17 to 20, 2024 in Munich. The award awardee will be invited to present their own research area in a short presentation during the Conference . The Division bears the costs of attending the conference. A prize committee, which is appointed by the two Divisions, decides on the award of the prize; each Division appoints two members.
Nominations and applications are possible. The doctorate of the candidates should not be older than ten years. Publications that appeared between 2019 and 2023 are considered. Each application/nomination contains the following information:
Please send your suggestion by e-mail and summarized in a PDF file to the GDCh Office for the attention of Maike Fries.
The Innovation Award 2023 was presented on April 4, 2023 at the Division conference "Frontiers in Medicinal Chemistry 2023" in Vienna
dr Matthew Schiedel awarded "in recognition of his outstanding, original and pioneering research work. By addressing intracellular allosteric binding sites of G protein-coupled receptors, Dr. Schiedel succeeded in developing novel concepts for controlling receptor selectivity and functional selectivity. By applying PROTAC strategies GPCRs could be targeted for proteasomal degradation. The scientific success of his innovative and independent work is impressively documented by publications in internationally renowned journals."
The Innovation Award was presented to Dr. Steffen Pockes and Dr. Awarded to Oliver Thorn-Seshold.
dr Pockes: "In recognition of his outstanding, original and pioneering research work. The scientific work of Dr. Pockes deals with the development of novel active substances to combat neurodegenerative diseases. The focus is on innovative ligands for G protein-coupled receptors and selective caspase inhibitors The scientific success of his innovative and independent research work is documented by publications in the highest-ranking journals of medicinal chemistry."
dr Thorn-Seshold: "In recognition of his outstanding, original and pioneering research work. Dr. Thorn-Seshold is developing novel, structurally chemical, photoswitchable modulators of the cytoskeleton. This work ranges from basic research to application in vivo. With photoswitchable antimitotics and vascular-damaging agents, new strategies for tumor therapy. The scientific success of his innovative and independent work is documented by publications in the highest international journals and by the considerable acquisition of third-party funds."
The Innovation Award was presented to Prof. Dr. Pierre Koch and Ass.-Prof. dr Nina Schützenmeister awarded.
prof dr Koch: "In recognition of his excellent, original and pioneering research work. Dr. Koch developed selective kinase inhibitors that are able to penetrate the central nervous system. These kinase inhibitors represent an innovative approach to the therapy of neurodegenerative diseases such as Alzheimer's dementia and multiple sclerosis. The scientific success of this innovative research work is documented by numerous publications in respected journals."
Prof. Dr. Schützenmeister: "In recognition of her excellent, original and forward-looking research work. Dr. Schützenmeister carried out innovative work on the synthesis of biologically active natural substances. She developed new and efficient synthesis methods and used them to obtain antibacterial and antiviral natural substances and natural substance analogues novel analogues for improving the biological activity are accessible. The scientific success of this innovative and extremely independent research work is documented by publications in respected journals."
The Innovation Award 2020 was awarded to PD Dr. Oliver Koch and PD Dr. Daniel Merk forgive.
PD dr Oliver Koch: " in recognition of his outstanding, original and pioneering research work. Dr. Koch carried out groundbreaking work on the development and application of computer-aided methods for the rational molecular design of new biologically active substances. In this context, he dealt in particular with targets for combating mycobacterial infections and for modulation epigenetic processes. The scientific success of this innovative and extremely independent research work is documented in numerous publications in respected journals."
PD dr Daniel Merk: " in recognition of his outstanding, original and pioneering research work. Dr. Merk carried out innovative work on the modulation of nuclear receptors. This important class of proteins offers poorly characterized, potential new targets for drug development. Dr. Merk used for his previous research work a wide range of methods, which also includes computer-assisted methods. In his young scientific career, he has already achieved an astonishing number of high-quality publications."
The Innovation Award 2019 was presented at the annual conference "Frontiers in Medicinal Chemistry" to Dr. Andreas Brunschweiger awarded "in recognition of his outstanding, original and forward-looking research work. Dr. Andreas Brunschweiger has developed and synthesized innovative DNA-encoded substance libraries for numerous substance classes. These libraries enable fast and efficient identification of new lead structures in drug research."
|2023||dr Matthias Schiedel, Erlangen-Nuremberg|
|2022|| dr Steffen Pockes, Regensburg|
dr Oliver Thorn-Seshold, Munich
|2021|| dr Pierre Koch, Regensburg|
Ass.-Prof. dr Nina Schützenmeister, Vienna
|2020|| PD dr Oliver Koch, Munster|
PD dr Daniel Merk, Frankfurt
|2019||dr Andreas Brunschweiger, Dortmund|
Prof. Dr. Finn K. Hansen, Leipzig
|2017||Prof. Dr. Anna Katharina Herta Hirsch, Saarbrucken|
dr Andreas Koeberle, Jena
|2015|| dr Nuska Tschammer, Erlangen
dr Peter Kolb, Marburg
|2014||Jun.-Prof. dr Peter Wich, Mainz|
|2013||dr Johanne Notni, Munich|
|2012||dr Christian Ottman, Dortmund|
|2011|| Jun.-Prof. dr Ingo Ott, Brunswick
dr Andreas Bender, Cambridge, UK
|2010||dr Daniel Rauh, Dortmund|
|2008||dr Franz von Nussbaum, Wuppertal|
|2007||Prof. Dr. Christoph Sotriffer, Marburg|
|2006||PD dr Andrea Sinz, Leipzig|
|2005|| PD dr Eric Beitz, Tuebingen
dr Holger Gohlke, Frankfurt
|2003||PD dr Franz F Paintner, Munich|
|2002||dr Jörg Rademann, Tuebingen|
|2001|| dr Andreas Link, Hamburg
dr Wolfgang Sippl, Dusseldorf
|2000||dr Manfred Jung, Munster|
|1999|| PD dr Thomas Carell, Zurich, Switzerland
dr Martin Schlitzer, Marburg
|1998|| Habilitation Prize|
dr Joachim Jose
dr Tanya Schirmeister
last modified: 25.08.2023 16:29 H from Translator